You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 121 No. 12, December 1986 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  PAPERS READ BEFORE THE 39TH ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, WASHINGTON, DC, MAY 12 TO MAY 14, 1986-PART II
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Suppressor Cell Activities in Autologous Human Tumor Systems

Suppression of Tumor Immunity

Bijay Mukherji, MD; M. T. Ergin, MD; Amala Guha, MS; Revati T. Tatake, PhD; Amgad L. Nashed, MD

Arch Surg. 1986;121(12):1404-1408.


Abstract



• Autologous T-cell clones or lines, established from peripheral blood lymphocytes (PBLs) and lymphocytes from tumor-affected lymph nodes, were used to examine the immunoregulatory circuitry that might influence cell-mediated cytotoxic responses against human cancers. In a chromium 51–release microcytotoxicity assay, PBLs, when activated in vitro against autologous tumor cells in interleukin-2, generated marked cytotoxicity against the autologous targets. In four solid-tumor systems, such generation of cytotoxicity in the PBLs could be suppressed by T-cell lines or clones derived from lymphocytes from tumor-affected lymph nodes (LNLs). The suppressions, mediated by both T8+ suppressor and T4+ suppressor-inducer cells, were restricted against only the autologous tumors in two systems. In the other cases, the suppressions were nonspecific. Clarification of the receptors through which these types of regulation are mediated might provide a new approach for immunotherapeutic manipulations in cancer.

(Arch Surg 1986;121:1404-1408)



Author Affiliations



From the Departments of Medicine (Drs Mukherji, Guha, Tatake, and Nashed) and Surgery (Dr Ergin), University of Connecticut School of Medicine, Farmington, and Hartford Hospital, Hartford, Conn.


Footnotes



Accepted for publication Sept 4, 1986.

Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 12, 1986.

Reprint requests to Departments of Medicine and Surgery, University of Connecticut School of Medicine, Farmington Avenue, Farmington, CT 06032 (Dr Mukherji).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.